359 results about "Glaucoma present" patented technology

Described here are systems and methods for accessing Schlemm's canal and for delivering an ocular device or fluid composition therein. The ocular devices may maintain the patency of Schlemm's canal without substantially interfering with transmural fluid flow across the canal. The fluid composition may be a viscoelastic fluid that is delivered into the canal to facilitate drainage of aqueous humor by disrupting the canal and surrounding trabeculocanalicular tissues. Tools for disrupting these tissues and minimally invasive methods for treating medical conditions associated with elevated intraocular pressure, including glaucoma, are also described.

The invention discloses a multi-modal data glaucoma classification method and system, a terminal and a medium, and the method comprises the steps: obtaining a color fundus image and an OCT image in different image modes, and carrying out the advanced feature extraction of the color fundus image and the OCT image based on a first feature extraction module and a second feature extraction module, the mode specificity characteristics of the two modes are obtained; fusing the mode specific features of the two modes based on a shallow feature fusion module to obtain shallow fusion features; inputting the mode specific features of the two modes and the shallow fusion features into a deep feature fusion module for fusion to obtain final fusion features; and based on a multi-layer perceptron classifier, performing classification prediction on the final fusion feature to obtain a classification result, the classification result including no glaucoma, early glaucoma or mid-late glaucoma. According to the method, through two-stage feature extraction, two-stage feature fusion and the classifier, accurate glaucoma classification can be obtained.

Described here are systems and methods for accessing Schlemm's canal and for delivering an ocular device or fluid composition therein. The ocular devices may maintain the patency of Schlemm's canal without substantially interfering with transmural fluid flow across the canal. The fluid composition may be a viscoelastic fluid that is delivered into the canal to facilitate drainage of aqueous humor by disrupting the canal and surrounding trabeculocanalicular tissues. Tools for disrupting these tissues and minimally invasive methods for treating medical conditions associated with elevated intraocular pressure, including glaucoma, are also described.

A wireless passive resonance sensor and contact lens for intraocular pressure monitoring comprises a contact lens body which is used for packaging a sensor assembly and serves as a substrate of the sensor. The first spiral inductor is arranged in the contact lens body; the middle elastic dielectric layer covers the first spiral inductor and is used for forming a deformable dielectric medium; the second spiral inductor is arranged on the middle-layer elastic dielectric layer, is opposite to the first spiral inductor and forms an inductor assembly with the first spiral inductor; wherein the first spiral inductor, the middle elastic dielectric layer and the second spiral inductor jointly form a capacitor and equivalently form a serial L-C-L resonant circuit, and the change of intraocular pressure is responded through the change of resonant frequency of the resonant circuit, so that passive wireless monitoring is realized. The design optimizes the preparation process, reduces the cost, improves the signal stability, is suitable for 24-hour continuous monitoring, and provides a powerful tool for early diagnosis and intervention of glaucoma.

The invention relates to the technical field of computer vision, in particular to a multi-modal intelligent glaucoma recognition method and system based on transfer learning, and the method comprises the following steps: collecting fundus images of a glaucoma patient in multiple stages based on medical image data, analyzing the texture and shape changes in the images, and obtaining a multi-modal image; and simulating changes of the pathological features in a plurality of development stages, and generating a dynamic pathological feature sequence. According to the method, retina changes of a glaucoma patient in multiple disease development stages are simulated, visual feature information of pathological features in multiple development stages is captured, visual features of fundus images of the patient are extracted and compared, the disease development stages of the patient are evaluated, and the feature recognition process is optimized in combination with transfer learning. The method improves the generalization ability of the model and the diagnosis accuracy, achieves the accurate evaluation of the visual impairment through combining the measurement and prediction of the intraocular pressure data, and helps medical personnel to judge the retina state of a glaucoma patient.

According to the glaucoma multi-mode auxiliary diagnosis device and the electronic equipment, firstly, first feature extraction and second feature extraction are carried out on an eye fundus image and an OCT image respectively, then semantic spaces of an eye fundus image mode and an OCT image mode are aligned by utilizing comparison loss, and the first feature and the second feature are fused by utilizing a cross attention mechanism, so that an eye fundus image is obtained. According to the method, the two modal data are subjected to fusion to obtain fusion features, then the fusion features are subjected to feature extraction to obtain third features, and glaucoma classification judgment is performed based on the third features, so that global modeling of the two modal data can be realized, effective features are extracted to perform glaucoma classification judgment, and the accuracy and timeliness of diagnosis are ensured.

The invention provides an eye drop composition as well as a preparation method and application thereof, and belongs to the technical field of ophthalmic preparations. The eye drop composition adopted by the invention is prepared from the following components: brimonidine tartrate, hyaluronic acid, collagen, trehalose and injection water. By compounding the components, the eye drops which can realize slow release of brimonidine tartrate and prolong the antihypertensive action time and have the characteristics of relieving blink discomfort, long-acting moisturizing, anti-inflammatory soothing, mildness, corrosion prevention and the like are prepared; the eye drops are beneficial to people suffering from glaucoma, intraocular hypertension, xerophthalmia, postoperative inflammation or allergy and preservative sensitivity or preservative allergy, the life quality is improved, and diseases are relieved.

The invention belongs to the technical field of medicines, and discloses an application of a Necrosulfenamide (NSA) compound in preparation of a medicine for resisting glaucoma trabecular network fibrosis. The NSA can inhibit abnormal activation of necroptosis-related pathways and significantly down-regulate fibrosis key factors, so that the structure and function of trabecular meshwork tissues are improved, and the aqueous humor outflow capacity is recovered. It is found for the first time that NSA not only has a stable and lasting intraocular pressure lowering effect, but also can reduce retinal ganglion cell damage in an intraocular hypertension state, and has definite treatment and protection effects on non-acute glaucoma and intraocular hypertension. The regulation effect of NSA on trabecular meshwork fibrosis is not disclosed in the prior art, the research blank in the field is filled, and a new pharmacological target and a clinical application strategy are provided for prevention and treatment of glaucoma and related intraocular hypertension diseases.

The present disclosure relates to fusion molecules and chimeric molecules which comprise two components: an Ang-2 antagonist peptide linked to a VEGF-binding moiety. Further disclosed are methods of using said chimeric molecules to treat a patient cancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).

1. Name of the design product: Graphical user interface for glaucoma gait feature setting of an electronic device. 2. Use of the design product: An electronic device. 3. Design key points of the design product: Lies in the graphical user interface. 4. Picture or photo that best shows the design key points: The front view of Design 1. 5. The electronic device is of a conventional design, and the rear view, left view, right view, top view, and bottom view are omitted. 6. Design 1 is designated as the basic design. 7. Use of the graphical user interface: The front view of Design 1 is the operation interface for logging in to the glaucoma gait feature construction system. The user clicks "Glaucoma-1" in the front view of Design 1 to enter Figure 1 of the interface state change of Design 1. The user clicks "01-1" in Figure 1 of the interface state change of Design 1 to enter Figure 2 of the interface state change of Design 1. The user clicks "celling light" in Figure 2 of the interface state change of Design 1 to enter Figure 3 of the interface state change; The front view of Design 2 is the operation interface for logging in to the glaucoma gait feature construction system. The user clicks "Glaucoma-1" in the front view of Design 2 to enter Figure 1 of the interface state change of Design 2. The user clicks "01-1" in Figure 1 of the interface state change of Design 2 to enter Figure 2 of the interface state change of Design 2. The user slides the left menu in Figure 2 of the interface state change of Design 2 and then clicks "Targets" to enter Figure 3 of the interface state change of Design 2; The user clicks "01Chest" in Figure 3 of the interface state change of Design 2 to enter Figure 4 of the interface state change of Design 2; The front view of Design 3 is the operation interface for logging in to the glaucoma gait feature construction system. The user clicks "Glaucoma-1" in the front view of Design 3 to enter Figure 1 of the interface state change of Design 3. The user clicks "01-1" in Figure 1 of the interface state change of Design 3 to enter Figure 2 of the interface state change of Design 3. The user slides the left menu in Figure 2 of the interface state change of Design 3 and then clicks "shengao" to enter Figure 3 of the interface state change of Design 3; The front view of Design 4 is the operation interface for logging in to the glaucoma gait feature construction system. The user clicks "Glaucoma-1" in the front view of Design 4 to enter Figure 1 of the interface state change of Design 4. The user clicks "01-1" in Figure 1 of the interface state change of Design 4 to enter Figure 2 of the interface state change of Design 4. The user slides the left menu in Figure 2 of the interface state change of Design 4 and then clicks "f666d6de-10c9-4c0f-8b" to enter Figure 3 of the interface state change of Design 2. 8. Other situations that need to be explained: Other explanations: The gray part in the picture is variable content. It can display different contents according to the user's personalized operations.

Disclosed are a series of isoquinolone derivatives as ROCK protein kinase inhibitors and uses thereof in preparing medicaments for ROCK protein kinase inhibitor-related glaucoma or ocular hypertension diseases. Specially, disclosed are a compound of formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.

Described here are systems and methods for accessing Schlemm's canal and for delivering an ocular device, tool, or fluid composition therein. The ocular devices may maintain the patency of Schlemm's canal without substantially interfering with transmural fluid flow across the canal. The fluid composition may be a viscoelastic fluid that is delivered into the canal to facilitate drainage of aqueous humor by disrupting the canal and surrounding trabeculocanalicular tissues. Some systems described here may be configured to cut or tear the trabecular meshwork with the body of an elongate member located within Schlemm's canal. Other tools for disrupting these tissues and minimally invasive methods for treating medical conditions associated with elevated intraocular pressure, including glaucoma, are also described.

The present disclosure relates to the treatment and / or prevention of glaucoma and other diseases affecting the optic nerve and retinal ganglion cells. In particular, the present disclosure provides novel therapeutic antibodies, and related compositions and methods, that target angiopoietin-related protein 7 (ANGPTL7) to reduce intraocular pressure (IOP) in order to prevent optic nerve damage and restore vision.

The invention discloses an application of a sophora flavescens ethyl acetate part and an active component thereof in resisting glaucoma trabecular meshwork fibrosis, relates to the field of biological medicines, and innovatively discovers the effect of the sophora flavescens ethyl acetate part and the active component thereof in resisting glaucoma trabecular meshwork fibrosis. The compound can be applied to preparation of drugs for resisting trabecular meshwork cell fibrosis and preventing and treating trabecular meshwork cell fibrosis related diseases such as glaucoma.

The invention discloses preparation of a light-operated adhesion anti-oxidation, anti-inflammatory and anti-fibrosis hydrogel implant and application of the light-operated adhesion anti-oxidation, anti-inflammatory and anti-fibrosis hydrogel implant in resisting glaucoma postoperative scars. The hydrogel disclosed by the invention is composed of a carboxymethyl chitosan derivative formed by modifying carboxymethyl chitosan with phenylboronic acid and o-nitrobenzyl alcohol respectively, and a polyphenol anti-inflammatory and antioxidant drug, wherein the phenylboronic acid modified carboxymethyl chitosan derivative and the polyphenol drug form a phenylboronic acid ester bond with active oxygen response; the o-nitrobenzyl alcohol modified carboxymethyl chitosan derivative is triggered by ultraviolet light and can form a dynamic covalent imine bond with an amino group on a tissue or a polymer. The hydrogel provided by the invention can enhance the adhesion to conjunctiva through light triggering at a glaucoma filtration wound part, and the viscous implant can realize an anti-fiber effect. In addition, the anti-inflammatory and anti-oxidation medicine loaded in the hydrogel can respond to wound active oxygen release, and postoperative wound oxidative stress and inflammatory response are relieved.

The invention relates to the technical field of animal disease models, and discloses a construction method of an intraocular hypertension animal model, comprising the following steps: step A, selecting an experimental animal; step B, preparing experimental instruments and reagents; c, in an anesthesia mode, deep anesthesia is carried out on the animal, and subsequent deep anesthesia is carried out; d, intraocular pressure measurement, wherein the basic intraocular pressure value is measured through anterior chamber injection. Step E, performing anterior chamber injection, and using ofloxacin antibiotic oculentum to prevent infection after an operation; and F, intraocular pressure measurement: measuring the change of the intraocular pressure value after the anterior chamber injection. According to the method, the natural pathological process of open-angle glaucoma is simulated by injecting IFN-beta into the anterior chamber, the situation that acute intraocular pressure rise is caused mainly by blocking an aqueous humor flow outlet channel like other models is avoided, and the method can better reflect the real situation of glaucoma diseases; in addition, the model avoids intraocular pressure change caused by anatomical structure change, so that the accuracy and reliability of the model are improved.

The invention discloses an application and method of SAH-CIM hydrogel in promoting survival of retinal ganglion cells in glaucoma. The hydrogel comprises a Y-type primitive composed of three DNA chains and a siRNA connector, and the nucleotide sequences of the three DNA chains are SEQ ID NO.1-SEQ ID NO.3; the method comprises the following steps: S1, constructing a Y-type primitive: mixing three DNA chains with equal molar concentration in an annealing buffer solution, performing high-temperature denaturation at 95 DEG C, and then quickly cooling to 4 DEG C to finish annealing, so as to form a stable Y-type structure with three-way cohesive ends; s2, synthesizing a siRNA (small interfering Ribonucleic Acid) connector; and S3, mixing the Y-type element and the siRNA connector according to a molar ratio of 1: 1.5 at room temperature to react for 30 minutes, and forming a three-dimensional network structure through complementary pairing driven self-assembly, thereby finally obtaining the SAH-CIM hydrogel. The SAH-CIM hydrogel provided by the invention can be used for preventing / treating ischemia-reperfusion injury and related diseases, for example, the SAH-CIM hydrogel can be used for treating glaucoma, accurate co-delivery of a neuroprotective agent and an immunomodulator can be realized, and the SAH-CIM hydrogel has the advantages of treatment accuracy and biocompatibility.

The invention relates to the technical field of glaucoma grading, and discloses a glaucoma grading system based on multi-modal conditional state space fusion, which comprises the following steps: acquiring a CFP image and an OCT image, and constructing a glaucoma grading network model which comprises a circular structure perception attention module, a layer prior enhancement axial attention module and a conditional state space fusion module; the circular structure perception attention module enhances the characterization capability of a circular key pathological change area in the CFP image, and the layer prior enhancement axial attention module enhances the utilization of key pathological change information in the OCT image; and the conditional state space fusion module dynamically modulates CFP spatial features through OCT global information, realizes cross-modal feature interaction, and performs glaucoma grading by using a trained network model. According to the method, multi-modal information can be effectively fused, the feature extraction capability of glaucoma related pathological features is enhanced, and the glaucoma grading performance is improved.

Described herein are devices used to treat high intraocular pressure and glaucoma. An example device includes a plate comprising a first surface opposite a second surface. The first surface includes a series of fluid channels. The device also includes a first coating on the first surface and a second coating on the second surface. The device is configured to lower intraocular pressure by draining aqueous humor from an anterior chamber to subconjunctival space of a patient's eye.

Surgical treatment of glaucoma involves creation of a sclerocorneal drainage channel, ensuring long-lasting controlled fluid flow and reduced intraocular pressure. Limitations relate to collateral damage to adjacent structures and outcomes being heavily reliant on the surgeon's expertise. The device described herein addresses such shortcomings. The device comprises a body for grasping, a piercing member including a proximal segment and a distal segment, the distal segment including a piercing tip at a distal end thereof, and a distal stabilizer element extending from a distal end of the body, the distal stabilizer element including a lumen, wherein the piercing member is configured to reciprocate from a stored position, wherein the proximal segment is retracted within the stabilizer lumen and the piercing tip extends outwardly from the stabilizer, and an extended position, wherein the distal segment and at least a portion of the proximal segment extend outwardly from the stabilizer.

Described here are systems and methods for accessing Schlemm's canal and for delivering an ocular device or fluid composition therein. The ocular devices may maintain the patency of Schlemm's canal without substantially interfering with transmural fluid flow across the canal. The fluid composition may be a viscoelastic fluid that is delivered into the canal to facilitate drainage of aqueous humor by disrupting the canal and surrounding trabeculocanalicular tissues. Tools for disrupting these tissues and minimally invasive methods for treating medical conditions associated with elevated intraocular pressure, including glaucoma, are also described.

The invention belongs to the field of application materials, and particularly relates to Ber-ApoEVs and preparation and application thereof.The Ber-ApoEVs comprise ApoEVs and Ber supported by the ApoEVs, the ApoEVs are bone marrow mesenchymal stem cell-derived apoptosis vesicles, and the Ber is berberine and a derivative thereof. Researches show that brand new Ber-ApoEVs play a synergistic neuroprotective role in the aspects of regulating and controlling polarization of microglial cells, release of inflammatory factors, p38 / MAPK signals and the like, neuroinflammation caused by retinal ischemia reperfusion (IR) can be relieved, retinal neuron apoptosis can be inhibited, and the Ber-ApoEVs can be used for treating glaucoma.

The invention relates generally to medical devices and methods for reducing the intraocular pressure in an animal eye and, more particularly, to stent type devices for permitting aqueous outflow from the eye's anterior chamber and associated methods thereof for the treatment of glaucoma. Some aspects provide a self-trephining glaucoma stent and methods thereof which advantageously allow for a “one-step” procedure in which the incision and placement of the stent are accomplished by a single device and operation. This desirably allows for a faster, safer, and less expensive surgical procedure.

The invention relates to an ophthalmology laser operation auxiliary positioning method, a storage medium and equipment, and relates to the technical field of ophthalmology laser operations. The method comprises the following steps: acquiring OCTA image data of blood vessels around the iris of a patient through optical coherence tomography angiography; processing the OCTA image data to identify blood vessel condition information; based on the blood vessel condition information, safe area coordinates avoiding the blood vessel position are generated; the safety zone coordinates are mapped to a surgical navigation system to guide implementation of a laser drilling operation. According to the technical scheme, OCTA imaging and processing are carried out on the blood vessels around the iris of the patient, the high-risk blood vessel position can be effectively recognized, and the safe punching area coordinates avoiding the blood vessels are generated based on the high-risk blood vessel position, so that the risk of complications such as bleeding in an operation is greatly reduced, and the operation efficiency is improved. And the safety of the closed-angle glaucoma laser peripheral iris resection is improved.

The invention discloses a magnesium alloy composite material and a preparation method and application thereof, and belongs to the technical field of magnesium alloy materials. The magnesium alloy composite material comprises a polymer and a magnesium alloy material, and the mass percentage of the magnesium alloy material in the magnesium alloy composite material does not exceed 50%. The composite material can be obtained by blending a polymer and a magnesium alloy material. The magnesium alloy composite material can be used for preparing devices or medicines for treating eye diseases, and is particularly used for preparing glaucoma drainage implantation instruments. Before magnesium alloy is degraded, the glaucoma drainage implantation instrument containing the magnesium alloy composite material is small in flow capacity, and low intraocular pressure can be prevented; after the magnesium alloy is degraded, a porous structure can be formed, so that the flow capacity of the drainage implantation instrument is increased, a normal drainage effect is achieved, and in addition, the magnesium alloy can also play a role in slowly releasing magnesium ions.

An adjustable flow glaucoma diverter is disclosed herein. For example, in one embodiment, an adjustable flow diverter may include an outflow drainage tube having a proximal inflow region and a distal outflow region. The proximal inflow region may include an aperture defining a fluid inlet range disposed at a location allowing fluid to flow therethrough. The diverter also includes an inflow control assembly located at the proximal inflow region. The inflow control assembly may include a control element configured to slidably mate with the proximal inflow region and a spring element. The spring element is configured to be activated by non-invasive energy and, upon activation, slidably move the control element along the proximal inflow region such that (a) the one or more apertures are accessible and have a first fluid flow cross-section, or (b) the one or more apertures are at least partially covered by the control element and have a second, different fluid flow cross-section.

The invention discloses an implanted micropump driving system and method for glaucoma treatment, and relates to the field of driving systems.The driving system comprises a receiving coil, a power management module, a microprocessor control module and a driving module, the receiving coil is connected with the power management module, and the microprocessor control module is connected with the driving module; the power supply management module is respectively connected with the microprocessor control module and the driving module, and the microprocessor control module is connected with the driving module; the driving method comprises the following steps that the receiving coil receives energy of the transmitting coil, the power management module converts the energy into a stable power supply voltage signal and transmits the power supply voltage signal to the microprocessor control module and the driving module, and the microprocessor control module generates an analog signal and a control signal; the driving module processes the analog signal and the control signal, outputs a high-voltage square wave signal, and drives the piezoelectric micropump through the high-voltage square wave signal; secondary injury to the patient is reduced, the micropump is accurately controlled, and the intraocular pressure of the glaucoma patient is effectively reduced.

The present invention relates to the application of an EphA2-specific tyrosine kinase inhibitor, ALW-II-41-27, in ophthalmic diseases. The present invention has confirmed that at a specific concentration, ALW-II-41-27 can inhibit the expression of EphA2 in the retina, reduce the damage of acute high intraocular pressure to retinal tissue, and improve the survival rate of retinal ganglion cells, thereby playing a neuroprotective role, and thus being used for the preparation of treatments for preventing and treating acute high intraocular pressure or glaucoma.

The present disclosure describes an optical probe for applying a laser light to at least the flat portion of the ciliary body and optionally other areas, such as the trabecular mesh, the ciliary crown and / or the ciliary sulcus of the eye, the present invention relates to methods, such as for treating glaucoma, reducing intraocular pressure (IOP), improving the outflow of aqueous humor from the eye, and / or reducing the accumulation of aqueous humor within the eye. The optical probe may be adapted for simultaneous treatment of a plurality of different regions, tissues, or eye bodies of the eye, or for sequential treatment of a plurality of different regions, tissues, or eye bodies of the eye.

The present invention discloses the use of a BCL3 inhibitor in the preparation of a drug for treating glaucoma. The present invention discovers the role of the BCL3 / NF-κB / NLRP3 signaling pathway in glaucoma and demonstrates that BCL3 inhibitors (such as JS-6) have never been reported to reduce retinal ganglion cell apoptosis and pyroptosis, and are therefore useful in treating glaucoma-related diseases.